CrossGen Wealth’s AbbVie ABBV Stock Holding History

CrossGen Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Buy	5,983 +503	+9%	+$108K	1.17%	27
2026 Q1	$1.19M	Buy	5,480 +363	+7%	+$80.5K	1.05%	28
2025 Q4	$1.17M	Buy	+5,117	New	+$1.17M	1.03%	29

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CrossGen Wealth's ABBV Position: Q2 2026 in Review

CrossGen Wealth increased its AbbVie (ABBV) stake by 9.2% in Q2 2026, buying an estimated $108K and bringing the position to 5,983 shares worth $1.51M. The position accounts for 1.17% of the portfolio, ranked #27.

CrossGen Wealth first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

CrossGen Wealth held 5,983 shares of AbbVie worth $1.51M as of Q2 2026.
CrossGen Wealth bought 503 AbbVie shares in Q2 2026, an estimated $108K.
AbbVie made up 1.17% of CrossGen Wealth's portfolio in Q2 2026, its #27 holding.
CrossGen Wealth first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CrossGen Wealth's 13F filing for Q2 2026, filed 24 Jul 2026.